BioRationality: Withdrawal of Proposed Terminal Disclaimer Rule Spells Major Setback for Biosimilars
The United States Patent and Trademark Office (USPTO)’s withdrawal of its proposed terminal disclaimer rule is seen as a ...
Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat ...
The proposed pertuzumab biosimilar QL1209 demonstrated equivalent efficacy and safety to reference pertuzumab (Perjeta) in ...
Steve Pickette, PharmD, BCPS, emphasizes that AI can streamline prescribing and formulary management for biosimilars and ...
A French real-world study found that the adalimumab biosimilar SB5 was effective in treating rheumatic or gastrointestinal ...
Number 5: Regulatory policies influence the availability of affordable biosimilars, with varying impacts across different jurisdictions. Number 4: The study findings demonstrate that the aflibercept ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback